Anserine inhibits carnosine degradation but in human serum carnosinase (CN1) is not correlated with histidine dipeptide concentration
Observational studyHumans
- Design
- Observational study
- Subjects
- 104 reference subjects for normal range; 7 male patients with liver cirrhosis
- What was measured
- Serum anserine and homocarnosine by HPLC, CN1 activity by fluorometry and CN1 concentration by a capture ELISA, in relation to the CNDP1 Mannheim allele and in liver cirrhosis.
What the authors reported
The CNDP1 Mannheim allele was associated with lower serum CN1 activity towards carnosine, anserine and homocarnosine, but activity did not correlate with serum dipeptide concentrations even though anserine and homocarnosine inhibited the enzyme. Patients with liver cirrhosis had very low CN1 activity (0.24 vs 3.2 micromol/mL/h) and concentration (2.3 vs 24.9 microg/mL) yet no increase in serum histidine dipeptides. The authors conclude that the protective effect of low CN1 activity is not explained by serum dipeptide levels.
Limits of this study
Small cirrhosis group; cross-sectional. Abstract only.
Source
PubMed 20971102 · doi:10.1016/j.cca.2010.10.016
Entry checked against PubMed abstract (E-utilities) on 2026-10-19. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.